Merck (MRK) Announces Presentation of Data from Three KEYTRUDA Studies; Strong Anti-Tumor Activity Observed
November 23, 2015 6:43 AM
Merck (NYSE: MRK) announced findings from three studies investigating the use of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in combination ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
